# CytoDyn, Inc. clinical trials: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with CytoDyn, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CytoDyn, Inc.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/cytodyn-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 17, 2026 | NCT07536815 | An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced... | CytoDyn, Inc. | Not applicable | Temporarily not available | TNBC, TNBC - Triple-Negative Breast Cancer, TNBC, Triple Negative Breast Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07536815) |
| November 21, 2024 | NCT06699836 | CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen | CytoDyn, Inc. | Phase 2 | Active not recruiting | Metastatic Colorectal Cancer (mCRC) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06699836) |
| February 16, 2023 | NCT05730673 | Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer | CytoDyn, Inc. | Phase 2 | Withdrawn | CCR5, Microsatellite Stable, Metastatic, Colorectal Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05730673) |
| March 9, 2022 | NCT05271370 | An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140\_CD03 Study | CytoDyn, Inc. | Phase 2/3 | Terminated | HIV-1-infection | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05271370) |
| December 22, 2020 | NCT04678830 | Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19 | CytoDyn, Inc. | Phase 2 | Completed | Coronavirus Disease 2019 | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04678830) |
| August 20, 2020 | NCT04521114 | Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis | CytoDyn, Inc. | Phase 2 | Completed | Nonalcoholic Steatohepatitis (NASH) | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04521114) |
| August 7, 2020 | NCT04504942 | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | CytoDyn, Inc. | Phase 2 | Completed | Solid Tumor, Adult | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04504942) |
| April 15, 2020 | NCT04347239 | Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19 | CytoDyn, Inc. | Phase 2 | Completed | Coronavirus Disease 2019 | 484 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04347239) |
| April 13, 2020 | NCT04343651 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | CytoDyn, Inc. | Phase 2 | Completed | Coronavirus Disease 2019 | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04343651) |
| March 18, 2020 | NCT04313075 | A Compassionate Use Study of Leronlimab in Breast Cancer | CytoDyn, Inc. | Not applicable | No longer available | Metastatic Triple-Negative Breast Carcinoma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04313075) |
| April 4, 2019 | NCT03902522 | PRO 140 in Treatment-Experienced HIV-1 Subjects | CytoDyn, Inc. | Phase 2/3 | Completed | HIV-1-infection | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03902522) |
| February 12, 2019 | NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC | CytoDyn, Inc. | Phase 1/2 | Terminated | Triple Negative Breast Neoplasms | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03838367) |
| December 13, 2016 | NCT02990858 | An Extension Protocol for Subjects Who Successfully Completed PRO140\_CD02 or PRO140\_CD02\_Open Label Study | CytoDyn, Inc. | Phase 2/3 | Terminated | Human Immunodeficiency Virus (HIV) | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02990858) |
| August 9, 2016 | NCT02859961 | Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection | CytoDyn, Inc. | Phase 2/3 | Completed | HIV | 562 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02859961) |
| May 3, 2016 | NCT02759042 | An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140\_CD02 Study | CytoDyn, Inc. | Not applicable | No longer available | HIV | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02759042) |
| April 13, 2016 | NCT02737306 | A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation | CytoDyn, Inc. | Phase 2 | Terminated | Graft Vs Host Disease | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02737306) |
| June 26, 2015 | NCT02483078 | Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 | CytoDyn, Inc. | Phase 2/3 | Completed | HIV | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02483078) |
| February 4, 2015 | NCT02355184 | An Extension of Protocol PRO 140\_CD01 Study | CytoDyn, Inc. | Phase 2 | Terminated | HIV, Human Immunodeficiency Virus | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02355184) |
| June 26, 2014 | NCT02175680 | Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection | CytoDyn, Inc. | Phase 2 | Completed | HIV, Human Immunodeficiency Virus | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02175680) |
| January 7, 2011 | NCT01272258 | A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral... | CytoDyn, Inc. | Phase 2 | Withdrawn | HIV | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01272258) |
| January 13, 2010 | NCT01048372 | Observational Study of Blood Treated With Cytolin | CytoDyn, Inc. | Observational | Completed | HIV Infections | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01048372) |
| March 25, 2008 | NCT00642707 | Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection | CytoDyn, Inc. | Phase 2 | Completed | HIV -1 Infection, HIV Infections | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00642707) |
| February 13, 2008 | NCT00613379 | PRO 140 by IV Administration in Adults With HIV-1 Infection | CytoDyn, Inc. | Phase 2 | Completed | HIV Infections | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00613379) |
| May 11, 2005 | NCT00110591 | Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers | CytoDyn, Inc. | Phase 1 | Completed | HIV Infections | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00110591) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 13 |
| Phase 2/3 | 5 |
| Not applicable | 3 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Terminated | 5 |
| No longer available | 2 |
| Withdrawn | 2 |
| Temporarily not available | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| HIV Infections | 4 |
| Triple Negative Breast Neoplasms | 3 |
| COVID-19 | 3 |
| Acquired Immunodeficiency Syndrome | 3 |
| Colorectal Neoplasms | 2 |
| Graft vs Host Disease | 1 |
| Non-alcoholic Fatty Liver Disease | 1 |
| Neoplasm Metastasis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Spring suppliers in the United States](https://specstream.ai/data/businesses/spring-suppliers/united-states)
- [Business management services in the United States](https://specstream.ai/data/businesses/business-management-services/united-states)
- [Hotel bars in the United States](https://specstream.ai/data/businesses/hotel-bars/united-states)
- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [B2B oil and gas exploration and development companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-exploration-and-development-companies/united-states)
- [Food and beverage distributors in the United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/united-states)
